Application of p53 gene mutation in cancer-associated fibroblasts

Abstract

The invention discloses application of p53 gene mutation in cancer-associated fibroblasts, and particularly relates to application of p53 gene mutation in the cancer-associated fibroblasts in screening and preparation of cancer therapy medicines. An experimental result shows that the growth of cancer can be promoted by mouse embryonic fibroblasts (MEF) carrying p53N236S mutation, thus it is suggested that p53 mutation activates the cancer-associated fibroblast characteristic of the MEF, and the favorable microenvironment is provided for multiplication, migration and the like of the cancer. Thenew function of p53 mutation in the cancer-associated fibroblasts is disclosed for the first time, through the discovery, the new idea and research direction are provided for p53 mutation in cancer research, a new action target is provided for cancer therapy, and a new strategy is also provided for cancer therapy.

Description

technical field

[0001] The invention belongs to the field of biotechnology, and in particular relates to the application of p53 gene mutation in tumor-associated fibroblasts in screening and preparing tumor therapeutic drugs. Background technique

[0002] Tumor is a major disease that seriously endangers human health. Its occurrence and development are a complex process; it not only involves cancer cells that drive the malignant process of tumors, but also includes various non-tumor stromal cells that constitute the tumor microenvironment. Among them, tumor-associated fibroblasts (cancer-associated fibroblasts, CAFs) are an important part of the tumor microenvironment. CAFs secrete chemokines, cytokines, inflammatory factors, etc., provide a favorable microenvironment for tumors, promote tumor growth, metastasis, and induce angiogenesis.

[0003] At present, tumor treatment mainly includes surgery, chemotherapy, radiotherapy, immunotherapy, hormone therapy and targeted gene...

Images